This phase II trial employs a prospective, randomized, parallel-group design to evaluate the efficacy and safety of hypofractionated radiotherapy combined with tislelizumab and surufatinib. Eligible patients are randomly assigned to one of two arms: Experimental Group A receives hypofractionated chemoradiotherapy plus concurrent tislelizumab and surufatinib, followed by consolidation therapy with tislelizumab plus surufatinib; Experimental Group B receives the same hypofractionated chemoradiotherapy plus concurrent tislelizumab alone, followed by tislelizumab consolidation.
Males or females aged 18 to 75 years or older;
Patients must have histologically or cytologically confirmed non-small cell lung cancer (NSCLC);
Unresectable Stage III disease according to AJCC 8th staging system;
Negative for known driver gene mutations；
Concurrent enrolment in another clinical study, unless it is an observational(non-interventional) clinical study;
Mixed small cell and non-small cell lung cancer histology;
Recent major surgery within 4 weeks prior to entry into the study (excluding the placement of vascular access;
Active or prior documented autoimmune disease within the past 2 years;